Oksana Koneva

CVRx sets agenda for HFSA2026 to advance Barostim program growth

CVRx sets agenda for HFSA2026 to advance Barostim program growth
CVRx plans Barostim focus at HFSA2026

CVRx is inviting attendees to HFSA2026 for an in-depth discussion on building and sustaining a successful Barostim program. The event will feature a comprehensive look at patient identification, referral pathways, multidisciplinary collaboration, and strategies for supporting long-term program development.

Esteemed faculty including Dr. Rachel will share their insights, offering valuable perspectives for clinical teams aiming to expand treatment options and enhance organizational growth in the heart failure space.

CVRx previously announced Barostim as a therapy designed to address root mechanisms of heart failure in patients, according to company statements. Progress with the technology has continued, with a sixth Barostim implant completed at The Mount Sinai Hospital earlier this year. These developments highlight ongoing efforts to broaden available treatment options for heart failure.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.